Hosted on MSN
Flibanserin and the journey to rediscover desire
Flibanserin, marketed as Addyi, is the first FDA-approved drug for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials show it can modestly increase sexual desire ...
TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences.
Industry Leaders lists, an expansion of the TIME100 Most Influential Companies issue that dives deeper into 20 sectors to ...
Epic Systems was named to Time’s list of the most influential health and life sciences companies of 2026. The ranking, released April 27, is part of Time’s expanded TIME100 Companies franchise, which ...
Add Yahoo as a preferred source to see more of our stories on Google. Ever wonder why there are 26 medications for male sexual disorders and only one drug for women who experience low libido? Perhaps ...
The MarketWatch News Department was not involved in the creation of this content. Recognition follows Addyi's newly expanded FDA approval to treat both premenopausal and postmenopausal women under age ...
RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the ...
Addyi is entering a period of explosive growth and cultural recognition, and our partnership with Near&Dear is about turning that momentum into impact: better access, smarter education, and women ...
PHIL expands direct-to-patient access to Addyi for as low as $40 per year with commercial insurance coverage or $149 per month cash whether accessed through telehealth or a doctor's office. SCOTTSDALE ...
PHIL expands direct-to-patient access to Addyi for as low as $40 per year with commercial insurance coverage or $149 per month cash whether accessed through telehealth or a doctor's office. The goal ...
U.S. health officials have expanded approval of a much-debated drug aimed at boosting female libido, saying the once-a-day pill can now be taken by postmenopausal women up to 65 years old. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results